SARS-CoV2 – Page 31 – Communicable Diseases Research

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

INVENT COVID 시험: COVID-19에 의해 유발된 급성 호흡곤란 증후군이 있는 피험자를 대상으로 정맥 이마티닙 메실레이트(Impentri®)의 효능과 안전성을 조사하는 무작위 대조 시험을 위한 구조화된 프로토콜

Study Protocol

Published on 2022-02-162022-09-10
Journal: Trials [Category] COVID19(2023년), MERS, SARS, 임상,

Evolutionary shift from purifying selection towards divergent selection of SARS-CoV2 favors its invasion into multiple human organs

Article

Published on 2022-02-152022-10-04
Journal: Virus research [Category] COVID19(2023년), MERS, SARS, 변종,

The impact of COVID-related perceived stress and social support on generalized anxiety and major depressive disorders: moderating effects of pre-pandemic mental disorders

Primary Research

Published on 2022-02-142022-10-28
Journal: Annals of General Psychiatry [Category] COVID-19,

Mortality Predictive Value of the C 2 HEST Score in Elderly Subjects with COVID-19—A Subanalysis of the COLOS Study

Article

Published on 2022-02-142022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review

Article

Published on 2022-02-122023-06-16
Journal: Postgraduate medicine [Category] COVID19(2023년), MERS, SARS,

[키워드] biologics COVID-19 Cytokine storm immunomodulation SARS-CoV2
[DOI] 10.1080/00325481.2022.2033563 PMC 바로가기

Adapting obstetric and neonatal services during the COVID-19 pandemic: a scoping review

Research

Published on 2022-02-112022-10-28
Journal: BMC Pregnancy and Childbirth [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS,

[키워드] abstracts Algorithms Ambulatory care anaesthesia Care Clinical protocols clinician Clinicians coronavirus Coronavirus infections COVID-19 Critical database effective eligibility criteria Health planning guidelines hospital Hospital planning Hospital restructuring Infection initial International international organization maintain maternity medical education medical staff medical subject heading modify Neonatal Neonate neonatology Obstetric Obstetrical obstetrics offered pandemic Pandemics Patient care planning Perinatal care perinatology Personnel management physical contact Postnatal care Pregnancy pregnant Prevalence Quality improvement recommendation recommendations representing researchers Residency training resource respiratory Result SARS-CoV-2 SARS-CoV2 School severe acute respiratory syndrome-related coronavirus 2 simulation training supplementary material thought Ultrasonography
[DOI] 10.1186/s12884-022-04409-4 PMC 바로가기 [Article Type] Research

SARS-CoV-2 infection increases risk of acute kidney injury in a bimodal age distribution

Observational Study

Published on 2022-02-112022-10-04
Journal: BMC Nephrology [Category] COVID19(2023년), Fulltext, MERS, SARS, 임상,

[키워드] 95% CI 95% confidence interval Acute kidney injury adjusted age Age-spectrum AKI Analysis baseline bimodal childhood children CIs Clustering Cohort Comorbidities confounders contribute COVID-19 creatinine criteria defined determine develop distribution dropped Epidemiology estimating equation evaluate example explained hospital Hospitalization hospitalized patient hospitalized patients Illness severity increase individuals International Logistic Mortality mortality risk Odds ratio Older age pandemic Patient Result risk risk factor SARS-COV-2 infection SARS-CoV2 SARS-CoV2 infection secondary Sex supplementary material turn
[DOI] 10.1186/s12882-022-02681-2 PMC 바로가기 [Article Type] Observational Study

Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial

보건 종사자의 Covid-19의 예방에 대한 하이드 록시 클로로 퀴인 : 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-02-092022-09-10
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 임상, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 assigned baseline clinical trial Complete coronavirus coronavirus disease COVID-19 effect size Effectiveness Efficacy and safety evaluate failure HCQ Health Health care Health care worker health care workers Health personnel high risk hospitalized patient hospitalized patients Hydroxychloroquine lack negative RT-PCR outcome Patient Placebo placebo group placebo-controlled Prophylaxis Randomized randomized clinical trial refusal reported respiratory Result Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 severe acute respiratory syndrome Coronavirus severe COVID-19 severe COVID-19 patients single center statistically significant subject symptomatic infection symptomatic SARS-CoV-2 infection The effect size the placebo group Trial with COVID-19
[DOI] 10.1371/journal.pone.0261980 PMC 바로가기 [Article Type] Randomized Controlled Trial

Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection

중화 항체를 포함한 SARS-COV2 체액 반응의 발달은 치명적인 감염으로부터 환자를 보호하기에 충분하지 않습니다.

Clinical Trial

Published on 2022-02-082022-09-01
Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] animal models anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies antibody Antibody Response asymptomatic individual Asymptomatic individuals asymptomatic patients breath characterized clearance COVID-19 COVID-19 patients Deceased development died disease severity form health emergency house humoral Humoral response IgA IgM immune response Immunological disorders in viral in-house ELISA Infection management modulation Neutralization assay Neutralizing antibodies neutralizing antibody pandemic passive transfer Patient patients persistence plasma PROTECT question recovered patient recovered patients Region reported SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 serum severe COVID-19 specific antibodies the antibody response the disease the RBD titers titers of IgG transfer Vaccine design Viral viral clearance virus-specific antibodies while
[DOI] 10.1038/s41598-022-06038-5 PMC 바로가기 [Article Type] Clinical Trial

AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome

AKR1B10, SARS-CoV2 중증 급성 호흡기 증후군에서 사이토카인 폭풍의 방아쇠 중 하나

Article

Published on 2022-02-082022-09-10
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘,

[키워드] Activation Acute respiratory failure AKR1B10 Analysis biological plausibility cell types contribute COVID-19 cytokine Cytokine storm Cytokines died drug treatment enzyme experiment expression extracellular vesicle Extracellular vesicles Factor form gene encoding highlight hospitalised COVID-19 patient hospitalised COVID-19 patients Hypothesis identify IL-1β IL-6 increased expression induce Inflammation inhibitor interleukin interleukin-1β interleukin-6 involved lipopolysaccharides LPS lung lung cells Macrophage macrophages management measurement modulation Occurrence outcomes over-expression Patient pharmacological target Preventing pro-inflammatory pro-inflammatory cytokine pro-inflammatory cytokines Protein reduced reducing Reductase respiratory Respiratory failure SARS-CoV2 secreted sera severe forms of COVID-19 severity significantly storm systemic impact the cytokine storm the disease TNF α TNFα transcriptomic data transferred treated Trigger Tumor tumor necrosis tumor necrosis factor
[DOI] 10.3390/ijms23031911 PMC 바로가기 [Article Type] Article